Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 6
Submit an article Journal homepage
338
Views
45
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

Hyun-Gyung Goh Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Yoo-Jin Kim Division of Hematology, The Catholic University of Korea, Seoul, Korea
,
Dong-Wook Kim MD, PhD Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea; Division of Hematology, The Catholic University of Korea, Seoul, KoreaCorrespondence[email protected]
,
Hyeoung-Joon Kim Department of Hematology/Oncology, Chonnam National University, Hwasun Hospital, Jeonnam, Korea
,
Soo-Hyun Kim Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Se-Eun Jang Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Jeong Lee Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Dongho Kim Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Wan-Seok Kim Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Sa-Hee Park Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
&
Il-Young Kweon Molecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
 show all
Pages 944-951 | Received 14 Jan 2009, Accepted 25 Mar 2009, Published online: 21 Jul 2009

Citations (45)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Eun-Jung Jang, Ju-Hee Bang, Ji-Young Byeun, Jin Eok Park, Hye-Rim Jeon, Yun Jeong Oh, Seung-Ah Yahng, Byung-Sik Cho, Ki-Sung Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Hee-Je Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park & Dong-Wook Kim. (2014) Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Hematology 19:2, pages 63-72.
Read now
Hyun-Gyung Goh, Min Lin, Takashi Fukushima, Giuseppe Saglio, Dongho Kim, Soo-Young Choi, Soo-Hyun Kim, Jeong Lee, Young-Seok Lee, Sang-Mi Oh & Dong-Wook Kim. (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leukemia & Lymphoma 52:5, pages 896-904.
Read now
Ryan Mattison & Richard A. Larson. (2009) Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. Leukemia & Lymphoma 50:6, pages 868-870.
Read now

Articles from other publishers (42)

Veselina Goranova-Marinova, Daniela Grekova, Vania Georgieva, Kalina Andreevska, Yana Gvozdeva, Margarita Kassarova & Zhanet Grudeva-Popova. (2023) Analysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria. Pharmacia 70:4, pages 1355-1362.
Crossref
Chethan R, Prabhat Singh Malik, Ranjit Kumar Sahoo, Surender Sharawat, Mayank Singh, Vikas Garg, Kanupriya Bhatia, Anura Kantak, Sunesh Kumar & Lalit Kumar. (2023) Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution. Annals of Hematology 102:8, pages 2087-2096.
Crossref
Elisabetta Abruzzese & Jane F. Apperley. 2021. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia 227 244 .
Richard E. Clark. (2019) Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. Current Hematologic Malignancy Reports 14:6, pages 507-514.
Crossref
Richard E Clark, Fotios Polydoros, Jane F Apperley, Dragana Milojkovic, Katherine Rothwell, Christopher Pocock, Jennifer Byrne, Hugues de Lavallade, Wendy Osborne, Lisa Robinson, Stephen G O'Brien, Lucy Read, Letizia Foroni & Mhairi Copland. (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology 6:7, pages e375-e383.
Crossref
. 2017. High-Risk Pregnancy. High-Risk Pregnancy.
Charles A. Schiffer. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 49 68 .
S H Han, S-H Kim, H-J Kim, Y Lee, S-Y Choi, G Park, D-H Kim, A Lee, J Kim, J-M Choi, Y Kim, K Myung, H Kim & D-W Kim. (2017) Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia. Leukemia 31:7, pages 1532-1539.
Crossref
Renuka Palani, Dragana Milojkovic & Jane F. Apperley. 2016. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia 161 175 .
Eilon Krashin & Michael Lishner. 2016. Managing Cancer during Pregnancy. Managing Cancer during Pregnancy 175 184 .
Silvia Mori, Elisabetta Vagge, Philipp le Coutre, Elisabetta Abruzzese, Bruno Martino, Ester Pungolino, Chiara Elena, Ivana Pierri, Sarit Assouline, Anna D'Emilio, Antonella Gozzini, Pilar Giraldo, Fabio Stagno, Alessandra Iurlo, Michela Luciani, Giulia De Riso, Sara Redaelli, Dong‐Wook Kim, Alessandra Pirola, Caterina Mezzatesta, Anna Petroccione, Agnese Lodolo D'Oria, Patrizia Crivori, Rocco Piazza & Carlo Gambacorti‐Passerini. (2015) Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study . American Journal of Hematology 90:10, pages 910-914.
Crossref
Renuka Palani, Dragana Milojkovic & Jane F. Apperley. (2015) Managing pregnancy in chronic myeloid leukaemia. Annals of Hematology 94:S2, pages 167-176.
Crossref
Harry P. Erba. (2015) Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission. American Journal of Hematology 90:3, pages 242-249.
Crossref
Seung-Ah Yahng, Eun-Jung Jang, Soo-Young Choi, Sung-Eun Lee, Soo-Hyun Kim & Dong-Wook Kim. (2014) Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population. International Journal of Hematology 100:2, pages 132-140.
Crossref
Kendra Sweet & Vivian Oehler. (2013) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?. Hematology 2013:1, pages 184-188.
Crossref
Michael J. Mauro. (2013) Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia. Leukemia Research 37:11, pages 1395-1403.
Crossref
Elizabeth A. Kuczynski, Daniel J. Sargent, Axel Grothey & Robert S. Kerbel. (2013) Drug rechallenge and treatment beyond progression—implications for drug resistance. Nature Reviews Clinical Oncology 10:10, pages 571-587.
Crossref
Hua Jin, Yiying Xiong, Jing Sun, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Dan Xu, Yongqiang Wei, Min Dai, Ru Feng & Qifa Liu. (2013) Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation. PLoS ONE 8:6, pages e65981.
Crossref
Sung‐Eun Lee, Soo Young Choi, Ju‐Hee Bang, Soo‐Hyun Kim, Eun‐jung Jang, Ji‐Young Byeun, Jin‐Eok Park, Hye‐Rim Jeon, Yun Jeong Oh, Hyeoung‐Joon Kim, Yeo‐Kyeoung Kim, Joon Seong Park, Seong Hyun Jeong, Sung‐Hyun Kim, Dae Young Zang, Sukjoong Oh, Dong Hoe Koo, Hawk Kim, Young Rok Do, Jae‐Yong Kwak, Jeong‐A Kim, Dae‐Young Kim, Yeung‐Chul Mun, Michael J. Mauro & Dong‐Wook Kim. (2013) Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. American Journal of Hematology 88:6, pages 449-454.
Crossref
Susan BranfordDavid T. YeungDavid M. RossJodi A. PrimeChani R. FieldHaley K. AltamuraAlexandra L. YeomanJasmina GeorgievskiBronte A. JamisonStuart PhillisBrad SullivanNancy E. BriggsMark HertzbergJohn F. Seymour, John Reynolds & Timothy P. Hughes. (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:19, pages 3818-3824.
Crossref
Mikael Daouphars, Marine Ouvry, Pascal Lenain, Jean Rouvet, Fabrice Jardin, Michael Bubenheim & Remi Varin. (2013) Preliminary Validation of Self‐assessment Tool to Measure Imatinib Adherence in Patients with Chronic Myeloid Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:2, pages 152-156.
Crossref
Stephen G. O’Brien & John M. Goldman. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 45 62 .
François-Xavier Mahon. (2012) Is going for cure in chronic myeloid leukemia possible and justifiable?. Hematology 2012:1, pages 122-128.
Crossref
R A Larson, A Hochhaus, T P Hughes, R E Clark, G Etienne, D-W Kim, I W Flinn, M Kurokawa, B Moiraghi, R Yu, R E Blakesley, N J Gallagher, G Saglio & H M Kantarjian. (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:10, pages 2197-2203.
Crossref
Dongho Kim, Hyun Gyung Goh, Soo-Hyun Kim, Soo-Young Choi, Sa-Hee Park, Eun-Jung Jang & Dong-Wook Kim. (2012) Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. International Journal of Hematology 96:1, pages 47-57.
Crossref
M Schemionek, T Spieker, L Kerstiens, C Elling, M Essers, A Trumpp, W E Berdel, C Müller-Tidow & S Koschmieder. (2011) Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. Leukemia 26:5, pages 1030-1037.
Crossref
Jennifer F T Teng, Vincent H Mabasa & Mary H H Ensom. (2012) The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic Myeloid Leukemia and Metastatic or Unresectable Gastrointestinal Stromal Tumors. Therapeutic Drug Monitoring 34:1, pages 85-97.
Crossref
Izhar Hardan, Anfisa Stanevsky, Yuliya Volchek, Tali Tohami, Ninette Amariglio, Luba Trakhtenbrot, Maya Koren-Michowitz, Avichai Shimoni & Arnon Nagler. (2012) Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia. Cytokine 57:2, pages 290-293.
Crossref
Dong-Wook Kim. (2012) Recent Advances of Management for Chronic Myeloid Leukemia. Korean Journal of Medicine 83:6, pages 718.
Crossref
Lina Eliasson. (2012) Treatment adherence in chronic myeloid leukemia: a systematic review of the literature. Clinical Practice 9:1, pages 87-100.
Crossref
Su Chu, Tinisha McDonald, Allen Lin, Sujata Chakraborty, Qin Huang, David S. Snyder & Ravi Bhatia. (2011) Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118:20, pages 5565-5572.
Crossref
Andrew M. Stein, Dean Bottino, Vijay Modur, Susan Branford, Jaspal Kaeda, John M. Goldman, Timothy P. Hughes, Jerald P. Radich & Andreas Hochhaus. (2011) BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment. Clinical Cancer Research 17:21, pages 6812-6821.
Crossref
Hagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, Carmino De Souza, Ian W Flinn, Leif Stenke, Yeow-Tee Goh, Gianantonio Rosti, Hirohisa Nakamae, Neil J Gallagher, Albert Hoenekopp, Rick E Blakesley, Richard A Larson & Timothy P Hughes. (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology 12:9, pages 841-851.
Crossref
Margaret von Mehren & Nicolas Widmer. (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?. Cancer Treatment Reviews 37:4, pages 291-299.
Crossref
Hanshi SunVaibhav Kapuria, Luke F. PetersonDexing FangWilliam G. Bornmann, Geoffrey Bartholomeusz, Moshe TalpazNicholas J. Donato. (2011) Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 117:11, pages 3151-3162.
Crossref
Jorge Cortes, Alfonso Quintás‐Cardama & Hagop M. Kantarjian. (2010) Monitoring molecular response in chronic myeloid leukemia. Cancer 117:6, pages 1113-1122.
Crossref
Y. Kobayashi. (2010) Molecular Target Therapy in Hematological Malignancy: Front-runners and Prototypes of Small Molecule and Antibody Therapy. Japanese Journal of Clinical Oncology 41:2, pages 157-164.
Crossref
Dong-Wook Kim. (2011) Recent advances in the path toward the cure for chronic myeloid leukemia. The Korean Journal of Hematology 46:3, pages 169.
Crossref
Dong-Wook Kim, Shripad D. Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, He Huang, Ian Irving, Saengsuree Jootar, Hyun-Gyung Goh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman, Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, Jianmin Wang & Raymond Wong. (2010) Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era. Leukemia Research 34:11, pages 1459-1471.
Crossref
Aya Kuwabara, Anna Babb, Amr Ibrahim, Dragana Milojkovic, Jane Apperley, Marco Bua, Alistair Reid, Letizia Foroni, Katayoun Rezvani, John Goldman & David Marin. (2010) Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116:6, pages 1014-1016.
Crossref
Jane Apperley. (2009) CML in pregnancy and childhood. Best Practice & Research Clinical Haematology 22:3, pages 455-474.
Crossref
John M. Goldman. (2009) Initial treatment for patients with CML. Hematology 2009:1, pages 453-460.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.